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What are the information priorities for cancer patients involved in
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Summary A total of 165 adult patients with Hodgkin's disease (HD) were questioned following treatment to
examine their perceptions of actual and desired involvement and provision of information in the treatment
decision-making process. Irrespective of the degree to which patients felt they had been involved in the
decision-making process and of the outcome of their particular treatment, patients who felt satisfied with the
adequacy of information given were significantly more likely to feel happy with their level of participation in
the overall process of decision-making (P<0.001). As part of a strategy investigating patient priorities,
patients were asked to rank a series of possible acute and late treatment-related morbidities. Counter-
intuitively, the majority of long-term survivors felt early short-term side-effects were more, or equally, as
important as late morbidity with respect to influencing choice of therapy. Unpredictable importance was
placed by patients on side-effects such as weight gain and fatigue in relation to other complications such as
infertility and risk of relapse. Patients do not necessarily share doctors' priorities in decision-making or place
the same emphasis on different types of morbidity. Experienced surrogates may assist us in understanding
patients' perspectives and priorities.
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Patients with early Hodgkin's disease were chosen for inves-
tigation of patients' perceptions of participation in decision-
making and information needs. This group represents a
cohort in which treatment and outcome are well documented.
Further, they represent a large group of patients with the
same final outcome following a variety of management paths.
Ten year survival rates for patients with stage I and II
Hodgkin's disease are now as high as 90% or greater in some
series (Crnkovich et al., 1987; Farah et al., 1988; Climeno et
al., 1992) using radiotherapy and/or chemotherapy. Despite
similar overall survival rates, single and combined modality
treatments are associated with differing spectrums of early
and late morbidity and risk of relapse necessitating salvage
treatment. In general, treatments with the lowest rates of
recurrence are favoured by clinicians, accepting some increase
in acute and late toxicity over regimens with higher relapse
rates. Assumptions are made in designing clinical trials as to
which side-effects are the most important, although their
significance relative to each other and to risk of relapse varies
between trials.
This implies that the decision regarding the most appropri-
ate therapy for a particular patient with early stage Hodg-
kin's disease should be influenced by the 'trade-off' they are
willing to accept between risk of relapse and side-effects.
While doctors and other health workers have knowledge of
disease and side-effects, their perception of these and their
relative priorities may differ from those of patients (Slevin et
al., 1990).
Factors enabling patients to enter into the decision-making
process effectively include firstly, their having adequate in-
formation and secondly, their being involved in discussions
regarding choice of therapy as much (or as little) as they
desire. Patient involvement in the initial decision-making pro-
cess may be hampered both by stress caused by the diagnosis
and lack of experience of the disease and possible therapeutic
options.
This study employed experienced surrogates to examine the
issues of patients' desire for information and involvement in
decision-making and to attempt to determine the relative
importance of various side-effects of disease and treatment.
Materials and methods
Patients treated for Hodgkin's disease between 1970 and 1991
age 18-50 with stage I-IIIa disease registered with and
treated within protocols of the British National Lymphoma
Investigation were sent two questionnaires. Patients had to
be free of known disease after a maximum of two relapses
and the consent of the managing consultant obtained before
mailing the questionnaires. A total of 260 patients were sent
the questionnaires and 165 patients (69%) returned the com-
pleted forms; 20 after reminder letters were sent. Patients
later found not to be within the 'required age range at
diagnosis (six), untraceable changes of address (18) and six
deaths accounted for some of the 95 'missing' questionnaires.
This brought the response rate in eligible patients up to
165/230 (72%).
Sixty-eight of the patients who replied were female and 97
were male. The median age of patients at the time of first
treatment was 28 years (range 18-50 years) and the median
interval from initial treatment to completing the question-
naire was 8 years (range 0-22 years).
The first part of the first questionnaire dealt with patients'
perceptions of the initial decision-making process, in partic-
ular the extent to which patients remembered feeling involved
in decisions regarding their treatment, their satisfaction with
this level of involvement and the provision of information
about the disease and therapy options. The types of treat-
ment experienced by that patient were recorded and if they
had received both chemotherapy and radiotherapy, they were
asked their overall impression of which treatment was most
difficult.
The second section aimed to identify disease and treatment
morbidities (both early and late) that patients felt were the
most important discriminants between different therapy
options. Patients were asked to specify which of a list of
symptoms or problems they had suffered during treatment
and in the years after treatment. They were asked to rank all
side-effects listed in order of importance with regard to the
degree they would influence a future decision regarding
cancer treatment. Patients were asked to rank all side-effects
in this way whether they had experienced them or not.
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However, some patients were not willing to rank side-effects
they had not experienced. For consistency therefore, and
because it seemed rational that information regarding acute
side-effects actually experienced would be most meaningful,
in analysing the acute morbidity data, only the symptoms or
problems each patient had experienced were included in the
importance ranking. For late morbidity, because numbers of
patients actually suffering the complications were small, as
long as patients had ranked every side-effect (whether they
had experienced it or not) their ranking was included for
analysis. A median importance rank across all patients was
determined and the percentage of patients ranking each side-
effect first, second or third in importance calculated for each
symptom or complication.
For the purpose of part of this analysis, patients were
divided into three groups on the basis of their overall
treatment-response experiences, the hypothesis being that
entirely positive, 'successful' treatment experiences, as opp-
osed to those with a negative or 'unsuccessful' component,
may influence future impressions of the 'preferred' treatment
option. Thus, patients who had completely responded to
initial treatment (either single modality or CMT) and who
had maintained a complete response (CR) were defined as the
(successful' group and their answers were compared with
those who had experienced 'unsuccessful' treatment scenar-
ios. This second group included patients that had either, (a)
gone into CR with first-line therapy but who had later
relapsed requiring further treatment and, (b) those who had
not achieved a CR with the first course of treatment and who
went onto a second treatment regimen that had not been
planned at the outset.
The whole of the first questionnaire was piloted on a
group of ten patients to test for ambiguity and then re-
piloted by circulation at a Hodgkin's Disease Association
Annual General Meeting (Maher et al., 1990). Some of the
questions were reformatted before sending further question-
naires.
The second questionnaire focused in more detail on both
physical and psychosocial changes following treatment. Ques-
tions were based on those derived by Fobair et al., (1986) to
evaluate potential disruptions in family and intimate relation-
ships, sense of well-being and employment. Most of these
data will not be presented here. Of direct relevance to this
study were data concerning a number of early and late
morbidities. In particular, patients' responses to questions
regarding energy levels and fertility have been examined
more closely to highlight issues relevant to data collection in
clinical trials.
Simple counts, proportions, chi-squared and analysis of
variance (ANOVA) were carried out on an Apple Macintosh
using Statview (Statview, 1992).
Results
Information and involvement
In response to the question regarding the adequacy of in-
formation given, 80 patients (48%) felt they had not had
enough information, 85 (51%) thought they had as much as
they needed and no patients felt they had been given too
much information. Fifty-one patients received written in-
formation about Hodgkin's disease and its treatment to take
away with them and of the 113 that did not, 102 patients
(90%) said they would have appreciated this.
The perceived level of patient involvement in the decision-
making process for all patients is shown in Table I. A total
of 102 patients (62%) indicated that they took no part in
decision-making and that the doctor had been responsible for
making all decisions on their behalf. Table II indicates that
95 patients (58%) were involved as much as they had wanted
to be and the remainder were either dissatisfied with their
level of involvement, could not remember or did not answer
the question. Overall, patients having 'successful' and
'unsuccessful' treatment experiences (as defined previously)
were equally likely to feel involved and satisfied with the
decision-making process. Despite reporting that they had
been adequately involved in the decision-making process,
25% of patients felt that there had been no real treatment
choices available to them.
Table III shows the relationship between patients' percep-
tions of the adequacy of information given at or around the
time of diagnosis and satisfaction with the level of involve-
ment in the decision-making process. Patients who felt that
they had been given sufficient information were statistically
significantly more likely to have felt satisfied with their par-
ticular level of involvement, irrespective of their perceived
degree of participation (or lack thereof). Sixty-seven of 77
patients (87%) happy with the information given were
satisfied with their level of involvement compared with 10 of
77 (13%) who were not (P<0.001; x2 test). Twenty-eight of
71 patients (39%) dissatisfied with the information given
Table I Perceptions of involvement in initial decision-making process in relation to
experience of treatment response (n = 165).
Successful (%) Unsuccessful (%) Total
No involvement-all 66 (63) 36 (60) 102
decisions made by
doctor
Participated but felt that 25 (24) 16 (27) 41
no real choices available
Participated and choices 6 (6) 6 (10) 41
available
Cannot remember/did 8 2 10
not answer
105 60 165
Table II Satisfaction with level ofinvolvement in decision-making according to treatment
experience (n = 165).
Successful (%) Unsuccessful (%) Total
As much involvement as 56 (53) 39 (65) 95
desired
Less involved than 35 (33) 18 (20) 53
would have liked
Cannot remember/ did 14 3 17
not answer
105 60 165
223
0
0Patient decision-making
S Turner etal
224
were happy with the degree to which they were involved and
the remaining 43 (61%) were not.
The 'success' or otherwise of the treatment experience did
not appear to have any significant influence on this
information/involvement relationship (ANOVA).
Perceptions ofacute and long-term morbidity
The median ranking for each early side-effect listed in the
questionnaire, the percentage of patients ranking it first,
second or third and the number of patients experiencing the
side-effect in question are shown in Table IV. Nausea and
vomiting (with a median rank of 1 out of 11 items) was the
side-effect viewed by patients as being the most important
cause of acute morbidity to be considered when choosing
between treatments with equal chance of cure. Ninety-three
per cent of 122 patients experiencing this side-effect ranked it
first, second or third. Change in physical appearance caused
by weight gain and/or hair loss, pain, fatigue during treat-
ment and sore mouth or difficulty swallowing all received a
median importance ranking of 3.5 or greater and were
experienced by 115, 56, 120 and 82 patients respectively.
Weight gain from steroids was a much more commonly
reported cause for concern in changed physical appearance
than alopecia. For each of these four symptoms, between
50% and 62% of patients experiencing them ranked them
first, second or third in terms of their influence on choice of
further treatment. Septic episodes requiring admission,
though only suffered by 19 patients, were felt by these
patients to be very significant with a median ranking of 2;
68% of these patients ranked serious infection in the top
three positions.
Of possible late complications, development of a second
cancer, relapse of Hodgkin's disease and cardiovascular com-
plications were thought to be the most important potential
problems to be considered when choosing between different
therapies, although numbers ofpatients experiencing many of
these problems were relatively small (Table V). The percen-
tage of patients ranking disease relapse requiring further
treatment as first, second or third in importance in the late
side-effect ranking was similar for the whole group of
patients (80%) as compared with the group of patients
actually experiencing a relapse of their disease (81%).
Data collected in the second questionnaire showed that 53
(32%) patients reported infertility following treatment. How-
ever, in the first questionnaire, only 21 (13%) patients ranked
this potential complication as first, second or third in impor-
tance relative to other late effects. Of 48 (out of 53) patients
reporting and ranking infertility, 15 of these ranked it first,
second or third compared with only 6 of 44 patients who
reported no fertility problems but who still ranked this late
side-effect. This difference was statistically significant (P
= 0.05). Thirty-five patients had had children (25 for the first
time) after treatment and in only nine cases did patients feel
'it may be difficult/impossible for me to have children
because of my Hodgkin's disease or its treatment'.
In the ranking section, 127 (73%) reported suffering from
fatigue as an acute side-effect of treatment. When asked in a
slightly different manner in the second questionnaire if their
disease or its treatment had caused any alteration in energy
Table III Relationship between satisfaction with information, involvement in decision-making
and success (S) or failure (F) of initial treatment
Satisfaction with involvement
Yes No
Satisfaction with information S F Total S F Total
Yes 41 26 67 6 4 10
No 15 13 28 29 14 43
Total 56 39 95 35 18 53
Table IV Importance ranking of acute side-effects
No. experiencing Percentage ranking
Potential side-effect side-effect Median rank 1, 2 or 3
Nausea/vomiting 122 1 93
Serious infection 19 2 68
Appearance change 115 3 62
Pain 56 3 59
Fatigue 120 3.5 50
Sore mouth/throat 82 3.5 50
Cough/breathlessness 103 5 5
Numb hands/feet 57 6 12
Change in bowels 56 6 16
Loss of sex drive 62 6.5 18
Taste alteration 90 7 8
Table V Late morbidity ranking by all patients (whether or not complication experienced) and number actually
experiencing complication
Potential late Percentage
complication No. experiencing No. ranking Median rank ranking 1, 2, 3
Development of second 0 97 1 88
cancer
Relapse of HD 38 104 2 80
Cardiovascular disease 8 93 2.5 71
Chronic energy loss 48 104 5 18
Infertility 53 106 5 25
Divorce/relationship 21 92 5 21
problem
Anxiety/depression 41 102 6 28
Impaired sex life 22 96 6 11
Occupation/life 30 95 6 16
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level, 156 patients (95%) said that energy levels had been
reduced and in 104 (67%) of these, energy levels had
remained decreased for several months after the treatment
period; longer than 12 months in one-third of cases. Forty-
six patients felt that their energy loss had never recovered up
to the time of completing the questionnaire. In relation to
influence on choice of therapy, patients gave long-term
energy loss a median importance ranking of 5 (on a scale of
1-9). There was no significant difference between the
incidences of energy reduction attached to differing treatment
modalities, however post treatment energy reduction was
slightly less common in patients receiving chemotherapy
alone (56%) than those having radiotherapy alone (62%) or
both treatment modalities (68%). The nature of the treat-
ment experience, i.e. successful or unsuccessful, did not
appear to impact on energy levels.
Of 76 patients receiving both chemotherapy and radio-
therapy, 18 (24%) thought that the overall experiences of the
two modalities were equally difficult, six that radiotherapy
was more difficult and 52 (68%) that chemotherapy was
worse than radiotherapy. Ninety-two of 152 patients answer-
ing the question (61%) thought that in general, when choos-
ing between treatments with the same chance of cure, short-
term, temporary side-effects in most people were most impor-
tant while 23 (15%) thought permanent late problems occurr-
ing in a few people years after treatment were more impor-
tant. Thirty-seven patients (24%) thought that acute and late
side-effects were equally important in deciding choice of
therapy.
Discussion
There is increasing emphasis on patient autonomy and
involvement in decision-making. This issue is particularly
relevant in the management of early stage Hodgkin's disease
in which there are often significant choices to be made
between different treatment options. Many investigators have
examined the concept of shared responsibility of patient care
and of active patient participation in decision-making
(Brody, 1980; Schain, 1980; Degner and Aquino Russell,
1988). This approach assumes that patients want to be
actively involved in decision-making, an assumption refuted
by some authors (Sutherland et al., 1989; Fallowfield et al.,
1994).
Our data indicate that there are many patients who are
satisfied with less than complete involvement, 26% of
patients feeling satisfied with the doctor taking full respon-
sibility for treatment decisions. Fifty-three patients (32%)
had been involved at least partially in the decision-making
process and the majority of these had been satisfied with this.
It is not possible to be certain if satisfaction was influenced
by the outcome of a therapy option chosen with or without
the patient's input; that is whether a more favourable out-
come (CR to initial treatment with no relapse) made the
decision-making process seem more satisfying in retrospect
than it actually was at the time, or would have seemed if the
patient had relapsed and required further treatment. Our
data imply, however, that treatment outcome has less
influence on satisfaction with involvement and its relation-
ship to information than might intuitively have been
expected.
Doctors are demonstrably poor judges of patient pref-
erences for involvement in their health care (Degner and
Aquino Russell, 1988). Desire for involvement in manage-
ment discussions and choices is affected by factors including
patients' age (Cassileth et al., 1980), sex (Blanchard et al.,
1988), cultural differences (Sensky, 1992) and time from
cancer diagnosis. This last variable may be related to the
stress around diagnosis inhibiting the ability to 'take on'
information given or to seek further information for mean-
ingful participation in management decisions, a problem
reported by several authors. (Ley and Spelman, 1967; Degner
and Aquino Russell, 1988). 'Prompt sheets' may facilitate
patient participation in cancer consultations (Butow et al.,
1994). Furthermore, the severity of illness may influence
desire for involvement. Ende et al. (1989) found that the
more serious the disease, the less inclined patients are to
participate in decisions. Strull et al. (1984) on the other hand
reported that asymptomatic outpatients with essential hyper-
tension similarly did not want an active role in management
decisions.
Desire for active involvement in making choices regarding
therapy is not well represented by a 'yes or no' model
(Cassileth et al., 1980). Nor does desire for participation
necessarily mean that patients perceive real choices; 25% of
our patients felt adequately involved without real choices
being available. Several authors have dealt with the impor-
tance of how choices are presented (Strull et al., 1984;
Richards et al., 1995). The reported benefits of providing
choice (patient satisfaction, reduced stress, increased comp-
liance, improved recovery) (Krantz et al., 1980; Tuckett and
Williams, 1984; Morris and Royle, 1988) must be balanced
against the potentially increased anxiety associated with res-
ponsibility for decisions and regret for perceived 'wrong'
decisions.
Another component of decision making is provision of
information (Degner and Beaton, 1987). Patient satisfaction
with health care has been directly linked to whether expecta-
tions of information from doctors are fulfilled (Degner and
Aquino Russell, 1988). Others (Ley and Spelman, 1967; Ende
et al., 1989; Fallowfield et al., 1994; Richards et al., 1995)
have stressed that desire for information is not necessarily an
expression of a desire to be involved in primary decision-
making. Ende et al. (1989) showed no correlation between
patients' information seeking and decision-making
preferences. Sutherland et al. (1989) found that many
patients actively sought information, but the majority prefer-
red the doctor to make treatment decisions. Like others
(Cassileth et al., 1980), Sutherland et al. demonstrate a
positive correlation between degree of information seeking
and level of preference for participation in decision-making.
Our results suggest that the importance of adequate inform-
ation may be in favourably influencing the overall experience
of the decision-making process rather than necessarily
encouraging participation in choosing treatments.
The amount and content of information given are only one
aspect. How information is given may sometimes be more
important than what is actually said (Tuckett and Williams,
1984). Some authors report that most patients asked directly
express a desire for maximal information (Cassileth et al.,
1980), but suggest that too much information may increase
stress, particularly at a time, e.g. soon after diagnosis, when
recall and assimilation of information are especially impaired
(Ley and Spelman, 1967; Blanchard et al., 1988). The present
study found that 90% of patients not receiving written in-
formation (62% of all patients) would have liked to have
received written material. Although we did not specifically
examine recall, these data would support the findings of
others (Ley and Spelman, 1967), that in most groups of
patients that less than half the information given was later
recalled. Penman et al. (1984) suggested that, although writ-
ten material was not as important as verbal information as a
remembered source of information, it may have other values
such as assisting communication between patients,
oncologists, patients' relatives and other doctors.
It is increasingly recognised that overall or even disease-
free survival are insufficient end points by which to compare
treatment strategies in Hodgkin's disease. Several inves-
tigators (Fobair et al., 1986; Newall et al., 1987; Bloom et al.,
1993; Olweny et al., 1993; Zeltzer, 1993) have examined the
adaption of survivors of Hodgkin's disease and stress the
importance of quality survival from both psychological and
physical points of view. The emphasis in this study was to
investigate the relative importance of different morbidities to
give guidance to the content of initial information 'packages'.
Nausea and vomiting were perceived as the most prob-
lematic acute side-effects, as reported by others (Coates et al.,
1983)). The introduction of 5HT antagonists may have some
bearing on this finding, although recent studies suggest that
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this remains a problem. The significance of septic episodes to
those who had actually suffered them highlight the difficulty
in conveying potential morbidities to people without exper-
ience of them. Symptoms assumed to be relatively minor,
such as sore mouth and change in weight, loomed large in
the patients' view. Similarly, energy loss was viewed as a
considerable problem. Energy loss as a cause of late mor-
bidity is rarely formally evaluated although the persistence of
fatigue into the longer term has been repeatedly reported
(Fobair et al. 1986; Bloom et al., 1990, 1993) and was noted
by 67% of patients in the current series. It was ranked at
least equal (if not greater) in importance to other late
psychosocial and physical complications with the exception
of relapse of Hodgkin's disease or development of a second
cancer or heart disease.
Infertility usually receives much attention and is often cited
as a reason for recommending one treatment regimen over
another. Clearly, this issue is crucial to many young patients.
However results of the current study do suggest that this may
be overemphasised when viewed from the perspective of the
whole patient group. In this series, in only nine cases (5%)
was Hodgkin's disease or its treatment felt to have rendered
them infertile or potentially infertile when they might other-
wise have had children. It should be noted that the British
National Lymphoma Investigation philosophy at that time
emphasised local therapy, at the cost of a slightly higher risk
of relapse, more than some other strategies. This may have
assisted in minimisig the fertility issue, although infertility
was still reported by a relatively large proportion of patients
(32%). Zeltzer (1993) found that in young adults, concern
regarding fertility following treatment was restricted to
women. Among Hodgin's disease patients treated at Stan-
ford University, 78 of the 165 patients wanting to conceive
following treatment (19% of all cases interviewed) were
unable to do so (Fobair et al., 1986). Kornblith et al. (1992)
examined fertility in advanced Hodgkin's disease patients
following treatment using an infertility index based on
whether the patients believed they were or had been proven
to be infertile or not. They found that although 53% were or
believed they were infertile, this parameter was actually not a
good predictor of survivors' overall psychological distress
and concluded that it is in fact not a critical issue affecting
long-term adjustment in Hodgkin's disease patients.
Our original hypothesis was that patients would rank risks
of long-term side-effects of more importance than short-term,
self-limiting and acute effects, but interestingly, patients
perceived early acute side-effects as being at least as
influential in determining choice of therapy as late, perma-
nent morbidity despite the fact that almost exactly equal
numbers of patients had some experience of early and late
morbidity: 78% vs 75% for early and late side-effects respec-
tively. It is a good example, however, of how difficult it can
be to guess what patients' priorities are likely to be; a fact
reported formally elsewhere. Zeltzer (1993) found similarly in
a study of adolescent and young adult cancer survivors that
acute side-effects of treatment were often the most vividly
remembered and were reported as the worst aspect of having
cancer. This must be acknowledged when offering increas-
ingly intense initial therapies.
The issues raised by this study do not necessarily assist
doctors in approaching the decision-making process for an
individual patient. It must be acknowledged that cognitive
dissonance affects patients' perception of the past; however,
experienced surrogates have nonetheless given us counter-
intuitive insights into the experience, preferences and
priorities of patients. One solution to the problems in desc-
ribing priorities might be to involve survivors in the design of
clinical trials, or in the initial information-giving process.
This approach has proved promising in other areas (Brad-
burn et al., 1995). These data suggest that although many
patients do wish for maximal participation in decision-
making, many patients would prefer the doctor to take full
responsibility for choice of therapy. Desire for information
was more universal and related to satisfaction with the entire
decision-making process. Desire for information and desire
for full participation in decision-making can not be equated.
Further, these data support the notion that doctors
treating Hodgkin's disease patients and designing trials in
which to enter them may not necessarily have identified the
outcomes that are of significance to patients themselves. It
appears that acute side-effects may be of as least as much
importance to patients as risk of late morbidity, and that
early and late effects not routinely examined such as energy
loss or change in appearance, may be more significant to
patients than others that are regularly examined. If we are
going to address the issues most pertinent to patients in this
and other areas of oncology then the relevant questions must
be incorporated into the design of future clinical trials. The
results of this study further emphasise the need for routine
use of validated self-report quality of life instruments.
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